Development of the thyroid hormone receptor beta-subtype agonist KB-141: a strategy for body weight reduction and lipid lowering with minimal cardiac side effects.
about
Thyroid Hormone Mimetics: the Past, Current Status and Future ChallengesObesity pharmacotherapy: current perspectives and future directionsNew avenues for regulation of lipid metabolism by thyroid hormones and analogsGuidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacementAssociation between polycyclic aromatic hydrocarbons and thyroid function among males and females: data from NHANES 2007-2008.A TRbeta-selective agonist confers resistance to diet-induced obesity.Thyroid hormone analogues and derivatives: Actions in fatty liverAdipose targets for obesity drug development.The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humansThyroid-disrupting chemicals: interpreting upstream biomarkers of adverse outcomes.Thyroid hormone analogs for the treatment of dyslipidemia: past, present, and future.Correlation of manganese with thyroid function in females having hypo- and hyperthyroid disorders.Thyroid function and serum copper, selenium, and zinc in general U.S. population.Field-based comparison of ligand and coactivator binding sites of nuclear receptors.The thyroid hormone receptor β-selective agonist GC-1 does not affect tolerance to exercise in hypothyroid rats.Direct effects of thyroid hormones on hepatic lipid metabolism.
P2860
Q26765178-22C26FDC-6310-439F-9033-06236F572F06Q26828559-22563376-ED37-4254-AF69-FA3FC5F8175AQ27003043-E1056E51-2762-4EE2-967C-01EE3DFD1BBAQ28649731-3C371E39-D710-4348-96E5-838D111F99D3Q31038240-1E2B7B6E-A8BF-44B3-8D91-401213536D4BQ35097051-25957A01-8259-4F86-9664-A043BDBFCD13Q35132642-31965D49-4FBF-4D10-BEDD-8E2DAA64E830Q36379383-73574EEB-D1BA-4E9D-9B60-96C9F50A01D4Q36392977-2DD18592-9293-46C1-A74A-A1AC4AFBD672Q37278918-1404C13C-4235-47E8-9B8B-BACE6AFDCDBFQ38684663-2D8D9864-6D2E-4FF5-9F58-40AE8A976D2DQ41214726-20EBBC36-CCEF-4031-87D5-3BCEB6BECB63Q45143903-C9DE962B-D855-4F88-94FF-9D201C360A75Q51814205-E627FF8E-46F6-40BB-991D-2EEB6F292E07Q53498471-04981EBB-5EBF-4BB5-AD34-286D822EBB2AQ55443852-C76F5B11-1FF7-487A-9F78-45806B4E8420
P2860
Development of the thyroid hormone receptor beta-subtype agonist KB-141: a strategy for body weight reduction and lipid lowering with minimal cardiac side effects.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Development of the thyroid hor ...... minimal cardiac side effects.
@ast
Development of the thyroid hor ...... minimal cardiac side effects.
@en
type
label
Development of the thyroid hor ...... minimal cardiac side effects.
@ast
Development of the thyroid hor ...... minimal cardiac side effects.
@en
prefLabel
Development of the thyroid hor ...... minimal cardiac side effects.
@ast
Development of the thyroid hor ...... minimal cardiac side effects.
@en
P2093
P2860
P1476
Development of the thyroid hor ...... minimal cardiac side effects.
@en
P2093
Gary J Grover
Johan Malm
Karin Mellstrom
P2860
P304
P356
10.1111/J.1527-3466.2005.TB00161.X
P577
2005-01-01T00:00:00Z